Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12446MR)

This product GTTS-WQ12446MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14981MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ8201MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ2933MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ5708MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ9259MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ10496MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ4811MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ5915MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW